Human disease models

Organoid
#Drug discovery #Human disease models #Organoids #Preclinical development #Webinar

Discover how organoids bridge the gap between the lab and clinic

Developing new drugs is a complex and often lengthy process. A major roadblock lies in the limitations of traditional preclinical models, which often fail to accurately represent the intricate biology of human patients. Join DDW for a free event on 18 June, 3PM… Read More

Webinar date:
Supported by HUB Organoids
#News

Organoid
#Drug discovery #Human disease models #Organoids #Preclinical development

From patient to petri dish: Replicating disease with patient-derived organoids

Developing new drugs is a complex and often lengthy process. A major roadblock lies in the limitations of traditional preclinical models. These models often fail to accurately represent the intricate biology of human patients. This webinar explores how patient-derived organoids (HUB Organoids) are revolutionising drug discovery by overcoming these challenges. Read More

Webinar date:
Supported by HUB Organoids
#Webinars

Researcher in a medical lab
#Anti-inflammatory #Assay development optimisation & technology #Human disease models #In vitro #In vivo

From in vitro to in vivo: Effective translation for anti-inflammatory treatments

John Unitt, Vice President, Immunology and Inflammation Drug Discovery, at Sygnature Discovery, explores the importance of an effective translational process for preclinical and clinical success. The global anti-inflammatory therapeutics market was estimated to be $98.26 billion in 2022 and is forecast to reach $146.14 billion by 2032, growing at a… Read More

#Exclusive Content

Mouse in laboratory
#Bispecific therapeutics #Drug discovery #Human disease models #Mouse models #Preclinical development #Preclinical investigations #Toxicology

Case Study: Streamline preclinical drug discovery

A new Case Study is now available to download for free: ‘In Vivo Evaluation Of Bispecific-Cell Engager Efficacy & Safety‘. Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. This platform identifies patient-therapy combinations at risk of developing… Read More

#News

#Bispecific therapeutics #Drug discovery #Human disease models #Mouse models #Preclinical development #Preclinical investigations #Toxicology

Streamline preclinical drug discovery: PBMC-humanised mouse models

Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. This platform identifies patient-therapy combinations at risk of developing severe inflammatory syndrome, a potentially fatal complication. Optimise the safety profiles of your immunomodulatory therapeutics before first-in-human trials by leveraging this platform. In… Read More

#Resources

#AI / data analytics / healthtech / informatics #Human disease models #Interview #Neurology #Neuroscience #Stem cells

Putting human data at the centre of drug discovery

Listen to this article on the DDW Podcast: James Peach is the Co-Founder and CEO of Human Centric Drug Discovery (HCDD), an Oxford University spin-out improving neurology drug discovery by bringing more human data to the process. Peach shared his insight with DDW’s Megan Thomas. MT: In what ways can human… Read More

#Exclusive Content #Opinion

Neuron
#ALS #Human disease models #iPSC #Neurology #Pluripotent stem cells #Stem cells #Whitepaper

Whitepaper: Explore iPSC-derived motor neuron morphology

A new whitepaper is now available from DDW and Sartorius entitled ‘iPSC-Derived Motor Neurons and Microglia From ALS Background Display Disease Phenotype’. Induced pluripotent stem cell (iPSC)-derived cells are a significant resource for disease modelling. They allow the use of cells directly from affected patients… Read More

#News

#ALS #Drug discovery #Human disease models #iPSC #Neurology #Pluripotent stem cells #Stem cells

Using patient-specific cells for disease modelling

Induced pluripotent stem cell (iPSC)-derived cells are a significant resource for disease modelling. They allow the use of cells directly from affected patients and have the potential to guide these cells towards multiple lineages. Download the whitepaper to: Explore iPSC-derived motor neuron morphology Discover how ALS disease phenotype… Read More

#Resources

Antibodies
#Guide #Human disease models #Mouse models #Pharmokinetics #Therapeutic Antibodies

Guide: Assessing preclinical PK in therapeutic antibodies

A new Guide is now available from The Jackson Laboratory (JAX) entitled ‘HuPK: A Humanised Platform for therapeutic antibody PK evaluation’. Download the Guide to learn more about:   How JAX’s HuPK™ Humanised FcRn Platform offers a validated and… Read More

#News

#Drug development #Drug discovery #Guide #Human disease models #Mouse models #Pharmokinetics

HuPK: A Humanised Platform for therapeutic antibody PK evaluation

Download the guide to learn more about:   How JAX’s HuPK™ Humanised FcRn Platform offers a validated and cost-effective solution for assessing the in vivo  preclinical pharmacokinetics and stability of Fc-based biologics and therapeutics carried by albumin.    JAX’s… Read More

#Intelligence #Resources

Saline intravenous (iv) drip in a child's hand
#Charles River #Human disease models #Oncology #Paediatrics #Preclinical investigations

Paediatric models for preclinical testing of oncology drugs

The US Food and Drug Administration’s (FDA) Research to Accelerate Cures and Equity (RACE) for Children Act now requires all oncology drugs to be tested for paediatric indications ahead of approval. The EU regulation of the European Medicines Agency (EMA) is also being adapted to mirror… Read More

#Cancer Research #News

Stem cells
#Human disease models #iPSC #Liver disease #Preclinical investigations #Stem cells #Webinar

Last chance: Discover how iPSC derived cells support drug development

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models… Read More

Webinar date:
Supported by DefiniGEN
#News

Pluripotent stem cells
#Human disease models #iPSC #Liver disease #Preclinical investigations #Stem cells #Webinar

Register now to discover how iPSC derived cells support gene therapy development

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models… Read More

Webinar date:
Supported by DefiniGEN
#News

Pluripotent stem cells
#Human disease models #iPSC #Liver disease #Preclinical investigations #Stem cells #Webinar

iPSC derived cells for developing drug and gene therapies

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models… Read More

Webinar date:
Supported by DefiniGEN
#News

Stem cells
#Human disease models #iPSC #Liver disease #Preclinical investigations #Stem cells #Webinar

How can iPSC derived cells can be used to support drug development?

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models… Read More

Webinar date:
Supported by DefiniGEN
#News

Pluripotent stem cells
#Human disease models #iPSC #Liver disease #Preclinical investigations #Stem cells #Webinar

How do iPSC derived cells support development of gene therapies?

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models… Read More

Webinar date:
Supported by DefiniGEN
#News